Maggie J. Rathos

<i>In vitro</i> antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00

Kalpana Joshi, Maggie J. Rathos, Rajendra Joshi et al. · Molecular Cancer Therapeutics · 2007 · 121 citations · Full text

Chemoprevention Strategy, Retinoblastoma Protein, Cell Cycle +16

P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant <i>in vivo</i> efficacy in tumor models

Kalpana Joshi, Maggie J. Rathos, P. Mahajan et al. · Molecular Cancer Therapeutics · 2007 · 74 citations

Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription

Sonal M. Manohar, Maggie J. Rathos, Vinay R. Sonawane et al. · Leukemia Research · 2011 · 57 citations

Hematological Malignancy, Medicine, Apoptosis +10

Potentiation of in vitro and in vivoantitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells

Maggie J. Rathos, Harshal Khanwalkar, Kavita Joshi et al. · BMC Cancer · 2013 · 40 citations · Full text

Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers

Maggie J. Rathos, Kavita Joshi, Harshal Khanwalkar et al. · Journal of Translational Medicine · 2012 · 40 citations · Full text